Table 4.

Incremental cost-effectiveness ratios (ICERs) for each of the vaccine scenarios compared with baseline (scenario 1).

Scenario	Cost (£)	QALY gained (discounted)	ICER (cost/QALY) (£)
Payer perspectivea
Scenario 2: 40% vaccine coverage of low-risk 50–64 y-olds	43,677,120	19,857	2,199.58
Scenario 3: 50% vaccine coverage of 50–64 y-olds	56,830,673	24,252	2,343.34
Scenario 4: 60% vaccine coverage of 50–64 y-olds	68,815,478	30,805	2,233.91
Societal perspectiveb
Scenario 2: 40% vaccine coverage of low-risk 50–64 y-olds	−309,788,990	19,857	−15,601
Scenario 3: 50% vaccine coverage of 50–64 y-olds	−374,269,663	24,252	−15,432
Scenario 4: 60% vaccine coverage of 50–64 y-olds	−476,316,868	30,805	−15,462

ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year.

^aCost estimates include GP, hospital, vaccine, and administration costs.

^bCost estimates include all factors included in Table 2 (GP visits, hospital, loss of productivity, vaccine, and administration costs).